Latest LentiVector(R) Stories
OXFORD, England, May 23, 2011 /PRNewswire-FirstCall/ -- - Six-Month Data From Third Cohort Presented at ASGCT 14th Annual Meeting - - Highest Efficacy Results to Date With 43% Average Motor Function Improvement - Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, announces that new data from the on-going Phase I/II trial of ProSavin(R) for the treatment of Parkinson's disease (PD) were presented at the American Society of Gene...
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.